Viral RNA purification

Use the **Invisorb® Spin Virus RNA Mini Kit** for reliable isolation of high-quality RNA from viruses found in a diverse range of starting materials. The kit simplifies viral RNA isolation by combining efficient lysis of the starting material and the inactivation of exogenous and endogenous RNases to prevent degradation. The isolated viral RNA is ready to use for various downstream applications like RT-PCR.

Product characteristics

- **Starting material:** up to 200 µl serum, plasma, cell-free body fluids, rinse liquid from swabs, cell culture supernatants; up to 50 µl whole blood; up to 1 x 10^6 mammalian cells; up to 20 mg tissue; stool suspension, sputum
- **Average yield:** depending on viral titer and starting material
- **Preparation time:** approx. 25 min

Benefits

- Safe handling of infectious samples by using capped spin columns
- Sensitive and accurate results at low viral titers
- For In Vitro Diagnostic Use (CE-IVD)*

*) Compliance with EU Directive 98/79/EC on in vitro medical devices (Not for in vitro diagnostic use in countries where the EU Directive 98/79/EC on in vitro medical devices is not recognized.)

Workflow



Ordering information

PRODUCT	PACKAGE SIZE	CATALOGUE NUMBER
Invisorb® Spin Virus RNA Mini Kit	50 purifications 250 purifications	1040300200 1040300300

stratec molecular

STRATEC Molecular GmbH
Berlin, Germany
www.stratec.com

Phone: +49 30 94 89 29 01
Fax: +49 30 94 89 29 09
E-mail: info.berlin@stratec.com

4A8j01/09/15

APPLICATION EXAMPLE

Sensitive detection of Norwalk Virus from stool samples



Viral RNA was isolated from 50 mg NLV infected fecal samples using the Invisorb® Spin Virus RNA Mini Kit. The extracted viral RNA was amplified on a Rotor-Gene™ 3000 using a NLV specific PCR. 10 µl of eluted NLV sample RNA was used per cDNA synthesis.

Data kindly provided by C. Helmeke, H-M., Irmscher, State Office of Consumer Protection, Saxony-Anhalt, Department Medical Microbiology, Magdeburg, Germany.

Selected references

Surveillance and vaccination coverage of measles and rubella in Northern Italy.
Amendola A, Bubba L, Piralla A, Binda S, Zanetti A, Pariani E, Ranghiero A, Premoli M, Pellegrinelli L, Coppola L, Gramegna M, Baldanti F, Zanetti A. Hum Vaccin Immunother. 2015;11(1):206-13

Site-specific S-acylation of influenza virus hemagglutinin: the location of the acylation site relative to the membrane border is the decisive factor for attachment of stearate.
Brett K, Kordyukova LV, Serebryakova MV, Mintaev RR, Alexeevski AV, Veit M. J Biol Chem. 2014 Dec 12;289(50):34978-89

Growth of influenza A virus is not impeded by simultaneous removal of the cholesterol-binding and acylation sites in the M2 protein.
Thaa B, Tielesch C, Möller L, Schmitt AO, Wolff T, Bannert N, Herrmann A, Veit M. J Gen Virol. 2012 Feb;93(Pt 2):282-92

Related products

PRODUCT	PACKAGE SIZE	CATALOGUE NUMBER
Invisorb® Virus RNA HTS 96 Kit/ C	4 x 96 purifications 24 x 96 purifications	7043300300 7043300400
InviMag® Virus RNA Kit/ KF96	1 x 96 purifications 5 x 96 purifications	7443300100 7443300200

stratec molecular

STRATEC Molecular GmbH
Berlin, Germany
www.stratec.com

Phone: +49 30 94 89 29 01
Fax: +49 30 94 89 29 09
E-mail: info.berlin@stratec.com

4A8j01/09/15